Vorasidenib, an oral dual inhibitor of mutant IDH1/2 enzymes, significantly improved progression-free survival in patients with grade 2 gliomas, a type of malignant brain tumor with poor long-term prognosis. This treatment delayed disease progression and was well-tolerated. These findings represent a significant step forward in the treatment of grade 2 glioma with IDH mutations. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2023
June 4, 2023
Patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation therapy before surgery based on the findings of federally funded research that will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) and simultaneously published in the New England Journal of Medicine (efficacy) and the Journal of Clinical Oncology (patient reported outcomes) on June 4, 2023. Omitting radiation therapy can reduce short- and long-term side effects that impact quality of life while providing similar outcomes in disease-free survival and overall survival.
June 2, 2023
Adding the targeted therapy drug ribociclib (Kisqali®) to hormonal (endocrine) therapy showed a significant improvement in invasive disease-free survival (iDFS) for people with HR-positive, HER2-negative early-stage breast cancer. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 2, 2023
Simple hysterectomy with pelvic node dissection is a safe treatment option for people with early-stage, low-risk cervical cancer and may help improve quality of life, according to results from a large, international phase III clinical trial. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 25, 2023
Adding the immunotherapy drug pembrolizumab (Keytruda®) to chemotherapy, with or without bevacizumab (Avastin®), improved overall survival (OS) and progression-free survival (PFS) in people with persistent, recurrent, or metastatic cervical cancer, regardless of whether the cancer expressed PD-L1. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 25, 2023
Patients with breast cancer in the overweight or obese body mass index (BMI) ranges can achieve meaningful weight loss through a telephone-based intervention. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 25, 2023
Medicaid Expansion Linked to Decrease in Mortality and Racial Disparities for People With GI Cancers
Two-year mortality and racial disparities in survival among patients with gastrointestinal (GI) cancers decreased in the time following Medicaid expansion in 2014. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 25, 2023
Five-year overall survival improved by 30% for children with acute lymphoblastic leukemia (ALL) who were treated at the Hospital General-Tijuana in Mexico, after implementation of a cross-border cancer treatment training and access program facilitated in partnership with Rady Children’s Hospital-San Diego and St. Jude Children’s Research Hospital. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and is in press with JCO Global Oncology for publication on Saturday, June 3.
May 25, 2023
Minimally invasive distal pancreatectomy with splenectomy is a safe and effective alternative to traditional open surgery for patients with resectable pancreatic cancer, according to results from DIPLOMA, an international randomized trial. This surgical approach, which removes tumors located on the body or the tail of the pancreas and the spleen, uses smaller incisions and offers a lower risk of serious complications compared to open surgery. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 9, 2023
Oncology professionals from around the world will convene in Chicago to discuss the latest clinical cancer research impacting patient care at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Optimizing care for patients, improving access to cancer care, and developing novel treatments are among the topics that will be highlighted in the meeting’s official Press Program.
April 19, 2023
Adding toripalimab to perioperative chemotherapy led to an improvement in event-free survival for patients with stage III resectable non-small cell lung cancer (NSCLC), according to research that will be presented during the April 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
April 19, 2023
In patients with KRASG12C mutated cancers, adagrasib, an oral drug that targets KRASG12C, may be an effective treatment, according to research that will be presented during the April 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
March 21, 2023
Zolbetuximab in combination with chemotherapy extends survival in patients with 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. These results will be presented during the March 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
February 18, 2023
Eight notable studies exploring new approaches in the treatment and management of genitourinary cancers will be presented at the 2023 ASCO Genitourinary Cancers Symposium, taking place February 16-18, 2023, at the Moscone West Building in San Francisco, California.
February 18, 2023
Eight notable studies exploring new approaches in the treatment and management of genitourinary cancers will be presented at the 2023 ASCO Genitourinary Cancers Symposium, taking place February 16-18, 2023, at the Moscone West Building in San Francisco, California.
Pages |